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Trauma has been shown to disrupt self-regulatory processes; emotion regulation deficits have 
also been implicated in the initiation and maintenance of substance use disorders (SUDs).  
Treatments for these complex comorbid problems utilize a variety of approaches.  However, to 
date, few studies have examined the effect of various available treatments on emotion 
dysregulation in this population.  This study extends the research on emotion regulation among 
the population with comorbid posttraumatic stress disorder (PTSD) and SUD.  This study is a 
secondary analysis of part of the data from a randomized clinical trial assessing the relative 
efficacy of two active treatment conditions for substance dependent individuals who also meet 
criteria for current DSM-IV-TR PTSD.  The current study examined features associated with 
emotion dysregulation, correlating dysregulation with PTSD and SUD symptoms; the study 
focused on baseline emotion dysregulation as a predictor of treatment outcomes.  Additionally, 
the study examined emotion dysregulation over time to determine the mutability of this complex 
factor in response to treatment.  Lastly, this study utilized a case illustration to examine in more 
depth change in emotion dysregulation over time, as measured by physiological arousal; this 
methodology provides for a more thorough depiction of the phenomenon.  Correlation analyses 
identified that baseline emotion dysregulation was associated with baseline PTSD symptom 
severity, but not with baseline substance use frequency among those with comorbid PTSD and 




received relapse prevention treatment showed no change in substance use frequency from 
baseline to follow-up.  Additionally, the high baseline dysregulation group that received 
Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure 
(COPE) showed a trending decrease in dysregulation at follow-up.  Altogether, this exploratory 
study provided evidence that exposure therapy can be tolerated by and beneficial to highly 
dysregulated persons with both PTSD and SUD and that psychotherapy focusing only on 
substance used may be contraindicated for highly dysregulated individuals with comorbid PTSD 
and SUD.  
Keywords: substance dependence, posttraumatic stress disorder, emotion dysregulation, 
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CHAPTER 1: INTRODUCTION 
Study Rationale 
The absence or impairment of emotion regulation abilities characterizes many 
psychological disorders of affect and thought.  For instance, chronic worry and stress, avoidance 
or restriction of emotions, abrupt shifts in emotions and moods, and inappropriate affect, are 
among the symptoms of emotion dysregulation that define many clinical disorders (Cole, Michel, 
& Teti, 1994).  Research has implicated emotion dysregulation in posttraumatic stress disorder 
(PTSD) and substance use disorders (SUDs; Savov & Atanassov, 2013; Schore, 2003).  The 
present study examined symptoms and features associated with high baseline emotion 
dysregulation among a population with comorbid PTSD and SUD.  Additionally, this research 
explored the role of emotion dysregulation for treatment outcomes.  Lastly, the study assessed 
the mutability of emotion dysregulation among people with concurrent PTSD and SUD. 
My interest in the area of emotion regulation arose from its critical role in adaptive 
functioning in stressful environments.  The ability to understand and modulate affective 
responses to stress has been linked to emotional resilience and has been identified as a protective 
factor against pathology (Allen & Fonagy, 2006).  Examining the relationship between treatment 
and emotion dysregulation will help to inform best practices relevant to clinical populations 
struggling with deficits in the area of emotion regulation. 
Study Aims 
 Emotion dysregulation is “inherent to many forms of psychopathology and may present 
in extremes of either avoidance and overly restricted emotional expression or heightened 
emotionality” (Bradley et al., 2011, p. 686).  Emotion dysregulation is a multi-faceted construct 






behaviors when experiencing emotional distress; a lack of access to adaptive strategies for 
modulating the intensity of emotional experiences; and an attempted avoidance of emotional 
distress (Gratz & Roemer, 2004).  Previous studies using non-clinical and community samples 
found associations between PTSD symptom severity and overall emotion dysregulation (Weiss, 
Tull, Anestis, & Gratz, 2013).  Similar associations were observed among a treatment-seeking 
cocaine dependent sample (McDermott, Tull, Gratz, Daughters, & Lejuez, 2009).  This study 
examined features associated with emotion dysregulation among a comorbid PTSD and SUD 
population.  This research examined correlations between baseline emotion dysregulation and 
symptom severity (e.g., PTSD and substance dependence).  It further sought to provide a more 
complete understanding of the relationship between emotion dysregulation and psychopathology 
among a comorbid PTSD and SUD population. 
A comorbid PTSD and SUD diagnosis is associated with a range of negative clinical 
outcomes including high risk for treatment dropout (Brady, Dansky, Back, Foa, & Carroll, 2001; 
Ford, Hawke, Alessi, Ledgerwood, & Petry, 2007), relapse following SUD treatment (Hien, 
Nunes, Levin, & Fraser, 2000; Najavits et al., 2007), more intense substance use patterns 
(Najavits et al., 2007), and high rates of high risk and self-destructive behaviors (Najavits et al., 
2007).  Despite these associations, few studies have examined psychological factors, such as 
emotion dysregulation, associated with these negative clinical outcomes.  This study examined 
emotion dysregulation as a predictor for treatment outcomes.  
Cognitive behavioral therapy (CBT) treatments are evidence-based interventions for 
PTSD and SUD (Foa, Keane, Friedman, & Cohen, 2008; van Dam, Vedel, Ehring, & 
Emmelkamp, 2012).  Additionally, CBT has been shown to be effective for PTSD and SUD 






prevention therapy (RPT), do not directly address trauma-related symptoms but instead focus on 
identifying high-risk use situations, bolstering coping strategies for managing relapse and 
cravings, finding ways to maintain lifestyle balance, and establishing more adaptive ways of 
responding to intense emotions.  Other CBT treatments for comorbid PTSD and SUD, such as 
Concurrent Treatment of PTSD and Substance Dependence Using Prolonged Exposure (COPE), 
utilize an exposure technique to directly and experientially address emotion regulation problems 
and associated physiological arousal through habituation in order to disrupt fear responses.  
Some research suggests that this type of therapy may be helpful in the treatment of comorbid 
populations (Mills et al., 2012).  Exposure therapy aims to help individuals assimilate and 
integrate their overwhelming experiences; addressing underlying dysregulation, which affects the 
intensity of the PTSD symptoms, may in turn reduce substance use.  This relationship between 
PTSD and SUD is consistent with the concept of the self-medication hypothesis (Khantzian, 
1997).  
High levels of emotion dysregulation are common among individuals with comorbid 
PTSD and SUD.  Clinicians are often hesitant to use exposure therapy with this population for 
fear that it is contraindicated and will lead to decompensation and/or dropout (van Minnen, 
Harned, Zoellner, & Mills, 2012).  Recent studies have challenged these assumptions and 
demonstrated the appropriateness of exposure therapy for treating comorbid PTSD and SUD 
(van Minnen et al., 2012).  Patients in these studies did not get worse or demonstrate high rates 
of relapse; instead, they demonstrated improvements with regards to both substance use and 
PTSD outcomes (Brady et al., 2001; Mills et al., 2012; Najavits, Schmitz, Gotthardt, & Weiss, 
2005; Triffleman, Carroll, & Kellogg, 1999).  The extant research, however, is primarily limited 






Additional research is necessary both to examine the extent to which treatment impacts emotion 
dysregulation among the comorbid PTSD and SUD population, and to determine the most 
effective and appropriate treatments for this population.   
The present study, using pre- and post-self-report measures, examined the change in 
emotion regulation over time and explored the effects of baseline dysregulation on treatment 
outcomes based on treatment type.  Lastly, exclusive reliance on self-report measures of emotion 
dysregulation is common among studies examining this psychological construct (e.g., Weiss et 
al., 2013).  Self-report responses may be influenced by the participant’s willingness or ability to 
report accurately on emotional responses.  Accordingly, in addition to self-report, this study 
examined changes in emotion dysregulation over the course of a 12-week treatment using a 






CHAPTER 2: LITERATURE REVIEW 
Overview 
The present study examined the relationship between treatment type and change in 
emotion regulation capacity in adults with comorbid PTSD and SUD, examining the effect of 
baseline dysregulation on treatment outcomes.  A literature review is presented in the next three 
sections, beginning with an overview of emotion regulation, briefly summarizing developmental 
and cognitive theoretical conceptualizations, and reviewing physiological mechanisms 
underpinning emotion regulation and stress response.  Additionally, emotion dysregulation 
among traumatized and substance dependent populations respectively is discussed.  Next, the 
relationship between trauma and addiction is summarized, addressing the prevalence of PTSD 
and SUD, and highlighting the pathways between PTSD and SUD.  The literature on several 
treatments that have been employed to effectively treat this comorbidity, such RPT and 
exposure-based treatments, is summarized.  Finally, literature on the use of exposure treatments 
with highly dysregulated populations is reviewed, and the connection between emotion 
dysregulation and acting-out behaviors is presented.    
Emotion Regulation 
Gross and Thompson (2007) aptly pointed out that the roots of contemporary research on 
emotion regulation reside in the early study of psychological defenses, psychological stress and 
coping, attachment theory, and emotion theory.  Emotion regulation1 involves monitoring, 
evaluating, and modifying internal feeling states and emotion-related physiological processes 
(Eisenberg, Cumberland, & Spinrad, 1998).  Ideal emotion regulation skills allow one to respond 
                                                 
1 This dissertation uses both the terms emotion regulation and emotion dysregulation.  Emotion regulation is used 
when referring to the successful monitoring, evaluating, and modifying internal feeling states and emotion-related 
physiological processes.  However, when emotion regulation is not successful, emotion dysregulation occurs, which 
is by definition considered to be a dysfunctional state.  This study was primarily focused on the mutability and 






in flexible and appropriate ways (Cicchetti, Ganiban, & Barnett, 1991; Snyder, Schrepferman, & 
St. Peter, 1997).  Emotion regulatory processes may be automatic or controlled, conscious or 
unconscious, and may dampen, intensify, or sustain emotions, depending on an individual’s 
goals (Gross & Thompson, 2007).  Various theorists have postulated different appraisal steps 
used to assess internal or external situations; these appraisals modulate and give rise to emotional 
responses.  
Developmental Conceptualization of Emotion Regulation 
Given the growing view that emotion regulation is a relational process, it follows 
logically that its early development occurs in the attachment relationship (Fonagy, Gergely, 
Jurist, & Target, 2002).  Schore (2003) underscored that it is within the attachment relationship 
that the primary caregiver shapes the development of the infant’s coping responses.  Although 
physiological, behavioral, and cognitive components clearly contribute to the emergence of 
emotion regulation skills, external factors—such as early interactions with caregivers—and 
direct methods of teaching children to behave in accordance with norms and expectations, also 
influence emotion regulation (Cicchetti et al., 1991).  Consequently, emotion regulation can be 
viewed as an adaptive strategy that a child learns through interactions with the caregiving 
environment to maintain the attachment relationship (Main & Solomon, 1990).  
Describing it as instrumental in fostering the capacity for emotion regulation, Fonagy et 
al. (2002) discussed affect mirroring, which they defined as the parent’s use of facial responses 
and vocalizations to represent an understanding of the infant’s feeling states, and to be calming 
rather than intensifying.  In addition, they suggested that self-reflection and the ability to reflect 
on the thoughts and feelings of others are capacities which are constructed, and have evolved 






infant’s affect, appropriate labeling of internal states does not occur, so that the affect remains 
both confusing and unsymbolized, and ultimately difficult to regulate (Calkins, 1994).  Through 
repeated affect-mirroring experiences, the child begins to learn that his or her mental state is 
decoupled from external reality.  Maladaptive early experiences with caregivers impact later 
development by limiting the ability to process or understand information related to mental states, 
which is critical to adaptive functioning in a stressful environment.  
Tronick (1989) emphasized the importance of the caregiver’s participation in interactive 
repair, which occurs when the infant’s stress is regulated externally by dyadic exchanges.  
Schore (1994) asserted that these micro-regulations lead to structural changes in the infant over 
time.  Schore (1994) referred to critical periods in the maturation of a child’s emotional system, 
stating, “The outcome of effective dyadic affect regulatory transactions is an integration and 
restructuring of the infant’s developing socioemotional system on a higher level of complexity” 
(p. 32).  By providing well-modulated affective stimulation, the caregiver facilitates the growth 
of connections between cortical structures that neurobiologically mediate self-regulatory 
functions (Schore, 1994).  Early object relational experiences, thus, directly influence the 
emergence of right-brain development and impact the ability to self-regulate emotional states 
(Schore, 1994).  Regions in the prefrontal cortex mature gradually into adolescence; thus, there 
are periods in development when relational experiences organize reactivity and emotion 
regulation.  
Neurobiological Response and Emotion Regulation 
Given the growing view that self-regulatory capacities have neurobiological correlates, 
the next section of this review discusses the connection between neurobiological response and 






emotion regulation and stress response (Herman, Ostrander, Mueller, & Figueiredo, 2005).  The 
hypothalamus, hippocampus, and regions in the prefrontal cortex all play significant roles in 
regulating the HPA axis.  The HPA axis is a complex set of interactions between the 
hypothalamus, the pituitary gland, and the adrenal glands.  
In response to an acute or chronic stressor, the hypothalamus, a small gland at the base of 
the brain serving as a regulatory center for body functions, releases corticotrophin-releasing 
factor (CRF) into the bloodstream.  The CRF travels, via blood vessels, to the pituitary gland, a 
pea-sized structure located below the hypothalamus.  In the anterior portion of the pituitary 
gland, CRF stimulates the release of adrenocorticotropic hormone (ACTH).  ACTH, in turn, 
travels through the bloodstream from the pituitary gland to the two adrenal glands, located on top 
of each kidney (Southwick, Ozbay, Charney, & McEwen, 2008).  The outer portions of the 
adrenals glands are stimulated by ACTH to release other hormones called glucorticoids such as 
cortisol.  The glucorticoids travel through the body as an adaptation to external stress.  The rise 
in glucorticoids prompts a cascade of reactions in the human body, including a rush of energy 
and alertness.  Glucorticoids like cortisol are also responsible for increasing blood sugar and 
breaking down proteins and fats to help mobilize energy (Southwick et al., 2008). 
Glucorticoids play an integral role in a negative feedback system to control the HPA’s 
reaction to stress.  If the stressor is mild, when glucorticoids reach the hypothalamus, further 
excess release of CRF into the blood vessels is inhibited by hormones to a normal level.  During 
times of intense stress, the hypothalamus signals for more CRF release; the inhibitory 








Cognitive-Behavioral Conceptualization of Emotion Regulation 
The limbic system, where the HPA axis is located, is the emotional center of the brain 
and is responsible for the identification, processing, and memory of a feeling state.  It is tasked 
with determining next steps when an emotion is triggered (Hien, Litt, Cohen, Miele, & 
Campbell, 2009).  With this in mind, the next portion of this review will discuss cognitive 
aspects of emotion regulation.  
Contemporary cognitive-behavioral conceptualizations of emotion regulation emphasize 
the role emotional arousal plays in adjusting decision-making processes, cueing behavioral 
responses, and enhancing or distorting memory (Gross & Thompson, 2007).  Emotions can be 
detrimental as well as helpful, depending upon their timing and intensity.  Emotion regulation 
describes the processes by which individuals influence which emotions arise, when they arise, 
and how emotions are experienced and expressed (Hien et al., 2009).  The ability to achieve 
goals, relate to others, and navigate life’s complexities depends upon the ability to appropriately 
regulate emotions.   
Emotion regulation was originally considered a demonstration of positive affect, but is 
now recognized to be a balance of both positive and negative affect.  In addition, as the concept 
of emotion regulation has evolved over time, the importance of how much one regulates 
emotions has diminished, and the importance of both the range of accessible emotional responses 
and the degree to which a response appropriately matches a given situation has increased (Gross 
& Munoz, 1995). 
A subset of emotion regulation strategies is made up of the conscious cognitive 
regulation processes.  Cognitive emotion regulation can generally be described as the 







strategies (Thompson, 1991).  These cognitive processes are essential to the management of 
stressful events, enabling the individual to manage and attempt to gain control over emotional 
arousal (Zlomke & Hahn, 2010).  Gross and Thompson (2007) described emotion regulation as 
having five core processes: (1) situation selection, (2) situation modification, (3) attentional 
deployment, (4) cognitive change, and (5) response modulation.  Situational selection and 
situational modification refer to both selecting and changing external situations to alter their 
emotional impact.  
Attentional deployment refers to the way in which individuals direct their attention in a 
given situation to influence their emotions (Gross & Thompson, 2007).  Two major attentional 
deployment strategies are distraction and concentration.  Distraction is the focusing of attention 
on different aspects of a situation, or moving attention away from a situation altogether in an 
effort to decrease arousal.  Concentration is increasing the focus on the emotional features of a 
situation.  
Emotion requires that percepts be imbued with meaning and that individuals evaluate 
their capacity to manage the situation (Gross & Thompson, 2007).  Cognitive change refers to 
altering how an individual perceives or appraises a situation, and adjusts the emotional 
significance by changing either how he or she thinks about the situation or about the capacity to 
manage the demands posed by the situation (Gross & Thompson, 2007).  Cognitive reappraisal, 
when used to down-regulate one’s negative emotional response, refers to the reframing of a 
negative stimulus in less emotional terms (McRae, Ochsner, Mauss, Gabrieli, & Gross, 2008). 
Response modulation refers to influencing physiological, experiential, or behavioral 







frequently referred to as suppression and are a result of an individual’s contextual assessment, as 
well as implicit and explicit social and societal demands (Gross & Thompson, 2007).  
In sum, research suggests that some combination of biological differences, environmental 
influences, social factors, and cognitive processes affect emotion regulatory capacities.  By 
establishing an understanding of the mechanisms underlying differences in emotion regulatory 
functions, the interrelated nature of the factors and their influence on each other is clearer.  
Measurement of Emotion Dysregulation 
Emotion dysregulation has been described as a multi-faceted construct.  In turn, many 
self-report instruments have been developed to measure various emotion regulation capacities 
(for a comprehensive list of measures see Aldao, Nolen-Hoeksema, & Schweizemeta, 2010).  
The Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004) represents the 
most comprehensive measure of the construct to date and it exhibited good reliability and 
validity in adults (Weinberg & Klonsky, 2009).  The DERS was designed to measure the 
complexities and clinically relevant difficulties of emotion regulation as described by several 
theories of emotion regulation (Sloan & Kring, 2007). 
On the one hand, because self-report measures are relatively easy and inexpensive to 
administer, they are commonly used in research settings.  On the other hand, the extent to which 
individuals are able to accurately report their experiences of dysregulation has not been 
confirmed (Tamir, Robinson, & Clore, 2002).  The accuracy of self-report measures depends, at 
least partially, on the participant’s insight, awareness, and capacity for metacognition (Cole, 
Martin, & Dennis, 2004).  Certain clinical populations, including traumatized populations, often 
have a diminished capacity to identify and label their emotional experiences which further 







Alternatively, researchers have utilized observational methods to study emotion 
regulation, usually by instructing participants to engage in an emotion-eliciting stimulus and then 
observing the resultant emotions, cognitions, and physiological responses (e.g., Nolen-
Hoeksema, Wisco, & Lyubomirsky, 2008).  With increasing popularity, physiological measures 
of autonomic activity have been used as markers of emotional arousal.  These measures of 
emotional arousal include electrodermal skin conductance, blood pressure, finger pulse, ocular 
startle reflex, pupil diameter, and heart rate (Bradley, Miccoli, Escrig, & Lang, 2008; Gross, 
2002).  Specifically, the present study used a skin conductance measure to detect rapid 
fluctuations in sweat gland activity in response to the sympathetic nervous system (Boucsein, 
1992); these fluctuations indicate changes in arousal and are markers for dysregulation.  A case 
illustration utilizing skin conductance data will be presented.  
The Impact of Trauma Upon Emotion Regulation 
One of the components of emotion dysregulation is a tendency for emotions to quickly 
escalate and change rapidly, be expressed in unmodified forms, and overwhelm both coping 
capacity and reasoning (Bradley et al., 2011).  Developmental research suggests that self-
regulatory deficits result from an interaction of several factors, including temperamental and 
biological variables, as well as intrusive, chaotic, and stressful early life experiences, including 
abuse, neglect, and problematic attachment relationships (Schore, 1994, 2003).  Emotion 
regulation skills allow for flexible and appropriate responses to stress and are essential to the 
development of many capacities, including optimal interpersonal functioning (Calkins, 1994; 
Cicchetti et al., 1991).  Schore (2003) suggested that early life trauma, relational abuse, or 







Chronic early traumatic stress can disrupt maturing emotion regulation functions and increase the 
risk of lifelong deficits in this area (Teicher, 2000).   
Some of the neurobiological alterations include the suboptimal functioning of the HPA 
axis.  The literature posits that glucorticoids act through two types of receptors participating in 
the stress response.  Type I maintains the capacity of the brain to respond to conditions that 
potentially threaten the organism.  Type II counteracts the impact of the other stress processes 
and returns the organism to pre-stress levels of functioning (Gunnar & Fisher, 2006).  Normally, 
the feedback loop allows the body to disable these defenses when the threat passes.  But in some 
cases, cortisol levels rise too often, or stay elevated too long (Gunnar & Fisher, 2006).  When the 
HPA axis is overactive, as in the case of chronic arousal, the negative feedback loop becomes 
progressively weaker (Gunnar & Fisher, 2006).  Repeated patterns of intense emotional 
experiences, like trauma exposure, may then lead to chronic changes in emotional sensitivity 
levels.  
The HPA axis functions in concert with several other neural pathways.  HPA 
dysfunctions are thought to likely to be associated with impaired integration of information from 
the amygdala, hippocampus, and prefrontal cortex (Herman et al., 2005).  Research in this area 
seems to indicate that a suboptimally functioning HPA axis may be either hypo-responsive or 
hyper-responsive, affecting the functioning of the sympathetic and parasympathetic nervous 
systems (Gunnar & Fisher, 2006).  Although this body of research is still not well developed, the 
hypothesized links between childhood trauma and neurobiological consequences are thought to 
involve over-programming of neurotransmitters impacting the stress response.  These irregular 
neurochemical responses are hypothesized to be detrimental to the brain during critical stages of 







to evidence that neurobiological changes in major structures in the limbic system lead to 
dysregulation of arousal systems (Schore, 2003).  
Emotion Dysregulation Among Substance Dependent Populations 
 Khantzian (1997, 2003) posited that substance users have difficulty tolerating negative 
emotions and managing overwhelming emotional states, and tend to use substances to achieve 
emotional stability.  Khantzian and others have also asserted that substance abusers have not 
developed adaptive defensive mechanisms to deal with rage and aggression (Duncan, 1975; 
Glover, 1932; Khantzian, 2003; Radó, 1933).  Aharonovich, Nguyen, and Nunes’s (2001) study 
examining levels of aggression and depression among individuals with SUDs, found higher 
levels of psychological distress in substance abusers than a non-clinical sample group.  A study 
examining the capacity for emotion comprehension and emotion management found that 
individuals with SUDs scored lower on these dimensions than a non-clinical control group 
(Hertel, Schutz, & Lammers, 2009).  Hien and Miele (2003) found that emotion-focused coping 
style mediates the relationship between substance use and aggressive behavior.  Together, these 
findings suggest that underlying emotion dysregulation contributes to an understanding of 
antisocial and aggressive behavior in this population.  These results support the theoretical 
literature which suggests that individuals who abuse substances and exhibit aggressive behavior 
are likely to have emotion regulation deficits.  
Emotion dysregulation and poor emotional coping skills have been identified as a risk 
factor for substance abuse disorders (Cooper, Frone, Russell, & Mudar, 1995; Thorberg & 
Lyvers, 2006).  Additionally, a recent meta-analysis implicated high negative affect, low positive 
affect, and low effortful control in the initiation and maintenance of SUDs (Cheetham, Allen, 







shown to induce cravings (Childress et al., 1994).  Research examining neurobiological 
substrates underlying SUDs highlight the dysregulation of brain reward and stress systems 
among this population (Cheetham et al., 2010; Koob, 2003).  In turn, individuals may use drugs 
or alcohol in an attempt to lessen the biological effects of a dysregulated stress response system.  
In sum, developmental research suggests that self-regulatory deficits result from an 
interaction of several factors, including temperamental and biological variables, as well as 
traumatic life experiences, including abuse, neglect, and problematic attachment relationships 
(Schore, 1994, 2003).  Schore (2003) suggested that early life trauma, relational abuse, or 
dysregulated attachment systems can produce specific patterns of neurobiological alterations.  
Neurobiological research on trauma and the stress response suggest that neurobiological changes 
lead to dysregulation of arousal systems (Schore, 2003).  Additionally, dysregulation and poor 
emotional coping skills have been identified as a risk factor for substance abuse disorders.  
Empirical and theoretical literature suggests that individuals who abuse substances and are likely 
to have emotion regulation deficits.  In conclusion, emotional dysregulation is a shared feature of 
both trauma and addiction. 
Trauma and Addiction 
 While comorbid individuals are often excluded from treatment research, all persons 
included in this study met criteria for both PTSD and SUD.  The following section will present 
the diagnostic criteria relevant to the clinical population under investigation.  Additionally, 
epidemiological data will be summarized, presenting the prevalence and incidence of SUD and 
PTSD in the population.  Lastly, the pathways between SUD and PTSD will be presented and the 
hypothesized underlying mechanisms relating the two conditions will be discussed, highlighting 







PTSD is a syndrome marked by the development of symptoms of intense horror or fear 
following a psychologically distressing event involving a real or perceived threat to physical 
well-being.  This disorder typically results from an extreme, catastrophic, or overwhelming real-
world experience and is typically accompanied by the following symptoms: re-experiencing the 
event through flashbacks, nightmares, and intrusive memories; avoidance of stimuli associated 
with the event; and increased arousal (American Psychiatric Association [APA], 2000).  
The Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.; DSM-IV-
TR; APA, 2000) provides diagnostic criteria for two forms of SUDs: substance abuse and 
substance dependence.  Substance abuse is characterized by a maladaptive pattern of use of a 
substance leading to clinically significant impairment or distress.  Maladaptive use is described 
as the repetition of at least one of the following: use in physically hazardous situations, 
substance-related legal problems, failure to fulfill major obligations, or interpersonal problems 
related to substance use.  Substance dependence, too, is a maladaptive pattern of use that is 
characterized by three or more of the following conditions: increased tolerance of the substance; 
onset of withdrawal symptoms; using larger quantities of a substance, increased frequency of 
substance use or use for a longer period of time than was planned; unsuccessful efforts to reduce 
or regulate use; significant time spent procuring, using, or recuperating from use; disruption of 
important social, occupational, or recreational activities; and continued use despite recognizing 
its negative impact on a physical or psychological well-being (APA, 2000). 
 This study utilized the DSM-IV-TR for diagnostic purposes; the DSM-5 (APA, 2013), 
however, has since been published.  The DSM-5 criteria for SUD are nearly identical to the 
DSM-IV-TR substance abuse and dependence criteria combined into a single list.  However, the 







of one or more criteria for a diagnosis of DSM-IV-TR substance abuse and three or more for 
DSM-IV-TR substance dependence.  Additionally, the PTSD diagnostic criteria have changed 
slightly.  The stressor criterion (Criterion A) is more explicit about the experienced “traumatic” 
events.  Furthermore, there were three major symptom clusters in DSM-IV-TR (re-experiencing, 
avoidance/numbing, and arousal).  In the DSM-5, there are four symptom clusters; the 
avoidance/numbing cluster is divided into two distinct clusters: avoidance and persistent 
negative alterations in cognitions and mood.  Because the criteria changes for these disorders 
were relatively minor, the findings from this study are likely generalizable to persons with 
comorbid PTSD and SUD as classified by the newer manual.  
A few large-scale epidemiological studies have been conducted among the general 
population to assess the prevalence of PTSD and SUDs.  One study indicated a 6.4% lifetime 
prevalence of PTSD and a 35.3% lifetime prevalence of SUDs (Kessler, Sonnega, Bromet, 
Hughes, & Nelson, 1995).  A second and more recent epidemiological study also estimated the 
lifetime prevalence of PTSD to be 6.4% (Pietrzak, Goldtein, Southwick, & Grant, 2011).  
Among individuals with PTSD, approximately 46% met criteria for SUD.  
The prevalence of comorbid PTSD and SUD can be examined in several ways.  One 
approach is to study the frequency of PTSD among those presenting with SUD, or conversely, 
the frequency of SUDs in those presenting with PTSD.  Among treatment-seeking samples, rates 
of comorbid PTSD and SUDs are high.  Individuals with PTSD were found to be up to 14 times 
more likely than patients without PTSD to have a SUD (Chilcoat & Menard, 2003; Ford, Russo, 
& Mallon, 2007).  According to current literature, prevalence estimates for PTSD in SUD 
samples vary from 11% to 41% (Harrington & Newman, 2007; Ouimette, Goodwin, & Brown, 







SUD and PTSD show higher symptom severities and worse treatment outcomes compared to 
patients with either disorder alone (van Dam et al., 2012).  
Although there is a well-established association between PTSD and SUD, the precise 
underlying mechanisms that relate the two conditions are unclear.  Three pathways have been 
hypothesized.  One, the high risk hypothesis, proposes that substance abuse leads to a higher risk 
for exposure to traumatic experiences, thereby increasing the opportunity for developing PTSD 
(Hien, Cohen, & Campbell, 2005).  A second, the susceptibility hypothesis, proposes that 
concurrent PTSD and SUD are due to an underlying, biological vulnerability, increasing the risk 
for developing both disorders independently following exposure to a trauma (Stewart & Conrod, 
2002).  Lastly, the self-medication hypothesis, posits that individuals with trauma histories and 
related PTSD frequently use substances in an effort to manage or avoid distressing symptoms 
and to relieve painful emotions or physical sensations associated with their traumas (Khantzian, 
1997; Stewart & Conrod, 2002).  
To date, the self-medication hypothesis is the only causal model with empirical support 
(Stewart & Conrod, 2002).  Chilcoat and Breslau (1998) conducted a study testing causal 
pathways between PTSD and SUD in a sample of 1,007 young adults.  Using a prospective 
design and analytical strategies testing for causal inference, the study was able to expound upon 
findings from cross-sectional design studies.  Support was only observed for only the self-
medication hypothesis.  
Additionally, Hien, Jiang et al. (2010) conducted a study examining the temporal course 
of improvement in PTSD and SUD symptoms among women in outpatient substance abuse 
treatment.  They found that PTSD symptom severity reductions were more likely to be 







substance use symptom reduction improving PTSD symptoms.  Results support the self-
medication model, using substances to cope with PTSD symptoms. 
Additionally, underlying emotion regulation deficits have been associated with the 
initiation and maintenance of SUD and may play an important mediating role between trauma 
exposure and subsequent substance abuse (Horowitz, Overton, Rosenstein, & Steidl, 1992; Suh, 
Ruffins, Robins, Albanese, & Khantzian, 2008).  Addiction literature suggests that emotion 
regulation deficits, including low tolerance for painful feelings and inability to self-soothe, are 
typical of substance abusers (Cheetham et al., 2010).  Krystal and Raskin (1970) proposed that 
because difficult emotions often remain somaticized, and unverbalized among substance abusers, 
people abusing substances are left ill-equipped to deal with their feelings.  Self-medicating with 
alcohol and drugs can provide temporary relief from the hyperarousal and numbing symptoms, 
the dysregulated feeling states that are characteristic of PTSD (Hien et al., 2009).  Though 
substance use may result in the short-term reduction of PTSD-related symptoms and attendant 
emotional distress, it is likely to have paradoxical consequences in the long term (Weiss et al., 
2013).  Substance use is theorized to prevent exposure to or awareness of corrective information 
and interfere with emotional processing (Foa & Kozak, 1986).  Thus, using substances to 
regulate emotions may exacerbate and prolong PTSD symptoms and emotion dysregulation in 
the long term, increasing motivations to use substances as an avoidant regulation strategy 
(Hayes, Wilson, Gifford, Follette, & Strosahl, 1996). 
Treatments for Comorbid PTSD and SUD 
The developmental and cognitive theoretical conceptualizations as well as the 
physiological mechanisms underpinning emotion dysregulation have been outlined above.  The 







requisite for optimal mental health.  Emotion regulation deficits common among traumatized and 
substance dependent populations have been implicated in the initiation and maintenance of 
comorbid PTSD and SUD.  Treatments for these complex comorbid problems utilize a variety of 
approaches.  However, to date, few studies have examined the effect of the various available 
treatments on emotion dysregulation in this population.  Additionally, there is a paucity of 
research which examines the effect of emotion dysregulation on treatment efficacy.  The present 
study will examine correlations between baseline emotion dysregulation and symptom severity, 
establish emotion dysregulation as a predictor for treatment outcomes, examine the extent to 
which treatment impacts emotion dysregulation among a comorbid PTSD and SUD population, 
and examine changes in emotion dysregulation over the course treatment.  
Clinical interventions for comorbid PTSD and SUD can be divided into two broad types: 
those which utilize prolonged exposure techniques (often also called present-focused or trauma-
focused) and those that do not.  Exposure therapy, directly and experientially, addresses emotion 
dysregulation problems and associated physiological arousal through habituation to disrupted 
fear responses.  The second type of treatment for comorbid PTSD and SUD focuses mainly on 
skills training, building coping strategies to manage overwhelming situations and emotions.  
While exposure therapy is currently considered one of the treatments of choice for PTSD alone 
(van Minnen et al., 2012), there is little consensus in the literature regarding the appropriateness 
of exposure therapy for highly dysregulated and comorbid PTSD and SUD populations.  With an 
eye toward the role of emotion dysregulation, the next section of this literature review provides a 
summary of clinical interventions used to address dysregulation and symptomatology associated 







Skills training treatments include interventions such as Seeking Safety (Najavits, 2002), 
CBT for PTSD in SUD treatment (McGovern et al., 2009), Substance Dependence PTSD therapy 
(Triffleman, Carroll, & Kellogg, 1999), Transcend (Donovan, Padin-Rivera, Kowaliw, 2001), 
and RPT (as described in Carroll, 1996).  The skill-training treatments are divided into 
integrative treatments, those that focus on PTSD and SUD simultaneously, and sequential 
treatments, those that treat the disorders one at a time.  The standard mode of care for comorbid 
PTSD and SUD in many substance abuse treatment programs is to treat the SUD first and to 
defer treatment of trauma-related issues.  The clinical rationale behind deferring trauma 
treatment relates to a fear of that unaddressed substance abuse could impede other therapeutic 
efforts and potentially cause relapse (Pitman et al., 1991).  The integrated model of treatment for 
comorbid PTSD and SUD requires that both disorders both be targeted simultaneously 
throughout the treatment.  The integrated model posits that addressing trauma early in a 
treatment and providing concurrent relief form PTSD symptoms improves recovery from SUDs 
(Back, 2010; Hien, Campbell, Ruglass, Hu, & Killeen, 2010).  
Hien, Cohen, Miele, Litt, and Capstick (2004) compared two skills training CBT 
treatments, Seeking Safety, a gold standard integrative treatment for PTSD and SUD and RPT 
with comorbid PTSD and SUDs.  RPT impacted both PTSD and SUD symptoms as effectively 
as Seeking Safety, the integrated treatment.  It is hypothesized that the skills gained through RPT 
generalized to PTSD-related difficulties including, for example, issues of self-care, safety, 
depression, and anxiety without direct emphasis on trauma in the treatment.  Overall, findings 
provided evidence that RPT is an efficacious, short-term treatment for comorbid PTSD and SUD 







and RPT may positively alter the emotion regulation capacities of individuals with comorbid 
PTSD and SUD.   
Alternatively, several approaches to treatments for comorbid PTSD and SUD utilize a 
two-pronged strategy, employing both skill training and exposure-based therapy simultaneously.  
These types of interventions include Seeking Safety plus Exposure Therapy-Revised (Najavits et 
al., 2005), Concurrent Treatment of PTSD and Cocaine Dependence (Back, Dansky, Carroll, 
Foa, & Brady, 2001) and COPE (Mills et al., 2012).  Experts in the field of substance abuse 
treatment, however, have historically been hesitant to use prolonged exposure to treat individuals 
with comorbid PTSD and SUD.  The exposure-based behavioral therapies, particularly those that 
involve imaginal re-experiencing of trauma, were suspected to be contraindicated for people with 
addictions, for fear of relapse, treatment dropout, increased acting-out behaviors, and 
dysregulation (van Minnen et al., 2012).  In sum, prolonged exposure was considered 
inappropriate for use among patients with SUD as it was believed that these patients would be 
unable to cope with the intense emotions triggered during exposure, placing them at increased 
risk for relapse (Foa & Rothbaum, 1998).  
 Acting-out behaviors can represent an attempt to cope with triggered or sustained 
posttraumatic emotional states, especially when these states overwhelm emotion regulation 
capacities (van der Kolk et al., 1996).  Interpersonal trauma may especially activate acting-out 
behaviors because it produces heightened negative emotional states and disrupts the biological 
and psychological aspects of emotional regulation that ordinarily serve to regulate intense 
emotion (Pearlman & Courtois, 2005).  Briere, Hodge, and Godbout (2010) conducted a study 
examining the relationship between interpersonal trauma, PTSD, emotion dysregulation, and 







not predict acting-out behaviors.  Instead such behaviors are triggered and reinforced by reduced 
emotion regulation capacity (Briere et al., 2010).  The relationship between acting-out behaviors 
and emotion regulation capacity reinforced concerns that PTSD treatments involving prolonged 
exposure may prove to be too activating for individuals who have a particular difficulty down-
regulating heightened negative emotional states.  
Alternatively, a recent empirical study examining the impact of dysregulation on the 
efficacy of prolonged exposure suggested that patients presenting with severe dissociative 
symptoms profit similarly from exposure treatment as do patients with minimal dissociative 
symptoms (Hagenaars, van Minnen, & Hoogduin, 2010).  The findings from this study challenge 
the assumed contraindication of employing prolonged exposure with dysregulated populations.   
 Until recently, prolonged exposure was considered theoretically inappropriate for use 
among patients with substance dependence (van Minnen et al., 2012).  It was widely believed 
that these dually diagnosed individuals would have difficulty coping with the intense emotional 
activation elicited by exposure therapy (Killeen, Back, & Brady, 2011).  Recently, the field’s 
skepticism has begun to be empirically addressed (Mills et al., 2012).  To date, existing research 
is primarily limited to smaller pilot studies (Brady et al., 2001; Coffey, Stasiewicz, Hughes, & 
Brimo, 2006; Triffleman et al., 1999).  Recently, however, one large randomized control trial 
evaluating the efficacy of prolonged exposure therapy for individuals with PTSD and SUD was 
conducted (Mills et al., 2012).  
The Mills et al. (2012) randomized control trial (N = 103) compared COPE plus usual 
treatment with usual treatment for substance dependence.  COPE consisted of 13 individual 90-
minute sessions with a clinical psychologist and usual treatment included any type of substance 







use of COPE plus usual treatment resulted in a significant improvement in PTSD symptom 
severity as compared to usual treatment.  Both treatment groups demonstrated significant 
reductions in severity of substance dependence, substance use, depression, and anxiety; however, 
the difference between groups was not significant.  
 Despite exposure therapy’s promise and significant efficacy in treating PTSD, the main 
clinical concern, which has likely limited the wider application of this techniques in comorbid 
PTSD and SUD populations, is tolerability.  The Mills et al. (2012) COPE study revealed that 
exposure did not worsen patients’ symptoms and in fact it significantly improved PTSD, 
substance use, and general psychiatric symptoms among treatment completers.  Emotion 
dysregulation appears to be a fundamental aspect of both trauma and addiction.  Treatments 
targeted to address this type of outcome have yet to examine (1) emotion dysregulation as a 
predictor for treatment outcomes, (2) the extent to which treatment impacts emotion 
dysregulation among a comorbid PTSD and SUD population, and 3) changes in emotion 
dysregulation over the course treatment.  The present study will provide additional empirical data 
to further inform the field about safe and efficacious treatments for this difficult-to-treat 
population. 
Study Aims and Research Questions 
PTSD and SUD are frequently comorbid with prevalence estimates varying from 11 to 
41% (van Dam et al., 2010).  Because comorbid PTSD and SUD is associated with poorer 
psychological treatment outcomes, and increased service utilization than either disorder alone, 
comorbid PTSD and SUD remains a serious public health concern.  Given the high prevalence of 







the disorders and to develop and evaluate treatment approaches appropriate for this vulnerable 
population.  
Trauma has been shown to disrupt self-regulatory processes; emotion regulation deficits 
have also been implicated in the initiation and maintenance of SUDs (Hien et al., 2005).  In sum, 
emotion dysregulation is a shared feature of both PTSD and SUD.  Treatments for these complex 
comorbid problems utilize a variety of approaches.  However, to date, few studies have 
examined the effect of the various available treatments on emotion dysregulation in this 
population.  
In conclusion, this study aimed to extend the research on emotion dysregulation among 
the comorbid PTSD and SUD population.  It examined features associated with emotion 
dysregulation, correlating dysregulation with myriad symptoms affecting this clinical population.  
Specifically, the study focused on baseline emotion dysregulation as a predictor of treatment 
outcomes.  The overall study offered three exploratory research questions. 
Rationale for Research Question 1 
Emotion dysregulation is inherent to many forms of psychopathology (Bradley et al., 
2011).  It is a multifaceted construct involving a lack of awareness, understanding, and 
acceptance of emotions; an inability to control behaviors when experiencing distress; a lack of 
access to adaptive strategies for modulating the intensity of emotional experiences; and an 
attempted avoidance of emotional distress (Gratz & Roemer, 2004).  Previous studies using non-
clinical and community samples found associations between PTSD symptom severity and overall 
emotion dysregulation (Weiss et al., 2013).  Similar associations were observed among a 
treatment-seeking cocaine dependent sample (McDermott et al., 2009).  This study will examine 







Specifically, the first research question will examine diagnostic features associated with emotion 
dysregulation at baseline.  
Research Question 1.  Will there be a relationship between baseline emotion 
dysregulation, as measured by the DERS, and baseline symptoms of PTSD and SUD, as 
measured by the Clinician-Administered PTSD Scale (CAPS) and Timeline Follow Back 
(TLFB)? 
Rationale for Research Question 2 
From a neurobiological perspective, several parts of the brain have been implicated in 
emotion regulation processes.  In particular, structures in the limbic system have been shown to 
play a role in learned emotional associations that become automatic over time (i.e., bottom-up 
processes).  Other structures in the brain, particularly areas located in the frontal lobes, have been 
implicated in the regulation of emotion (i.e., top-down processes).  Exposure-focused treatments 
and skills-based treatments are premised on different understandings of emotion dysregulation.  
RPT aims to change behavior through a top-down approach, examining cognitions in relation to 
affect.  COPE, the only exposure treatment developed to treat SUD, utilizes a bottom-up fear 
habituation processing approach.  Specifically, the second research question explored whether 
baseline emotion dysregulation is a predictor for treatment outcomes.  
Research Question 2.  Will treatment type moderate the relationship between baseline 
dysregulation, as measured by the DERS, and treatment outcomes, as measured by the CAPS 
and substance use days in the last 7 at follow-up? 
Rationale for Research Question 3 
To the extent that certain emotion regulatory strategies are theorized to be more adaptive 







regulatory capacities.  Empirical evidence that treatment, in fact, alters emotion regulation is 
currently sparse.  Demonstrating how emotion regulation is changed by therapy is an important 
avenue for future research.  
Because self-report measures are relatively easy and inexpensive to administer, they are 
commonly used in research settings.  The accuracy of self-report measures depends, at least 
partially, on the participant’s insight, awareness, and capacity for metacognition (Cole et al., 
2004).  Certain clinical populations, including traumatized populations, often have a diminished 
capacity to identify and label their emotional experiences which further complicates the 
usefulness of self-report measures.  
Alternatively, researchers have used observational methods to study emotion regulation, 
usually by instructing participants to engage in an emotion-eliciting stimulus and then observing 
the resultant emotions, cognitions, and physiological responses.  Despite compelling reasons to 
use multiple methods to assess emotion dysregulation, few studies have done so.  This study 
however, used a skin conductance measure to detect rapid fluctuations in sweat gland activity in 
response to the release of acetylcholine by the sympathetic nervous system (Boucsein, 1992); 
these fluctuations indicate changes in arousal. 
Specifically, the third research question examined change in emotion dysregulation pre- 
and post-intervention as well as over the course of treatment.  
Research Question 3.  Will treatment type moderate the relationship between baseline 
dysregulation, as measured by the DERS, and emotion dysregulation at follow-up, as measured 








CHAPTER 3: METHOD 
Study Design 
This dissertation research is a secondary analysis of part of the data from a randomized 
clinical trial assessing the relative efficacy of two active treatment conditions for substance 
dependent individuals who also met criteria for current DSM-IV-TR PTSD.  Eligible participants 
(see inclusion and exclusion criteria below) were randomly assigned to: (1) COPE, (2) RPT, or 
(3) delayed treatment.  The study was a three-armed randomized controlled trial with repeated 
outcome measures at baseline; post treatment; and 1, 2, and 3 months post-treatment.  Trained 
therapists administered the behavioral interventions on an individual basis for 12 one-hour 
weekly sessions.  
 This 2 × 2 pre-post control group design study examined the correlation between baseline 
emotion dysregulation (as measured by the DERS, a self-report measure) and symptom severity 
at baseline (as measured by the Clinician-Administered PTSD Scale and the Timeline Follow 
Back).  Secondly, the study examined baseline emotion dysregulation as a predictor for treatment 
outcomes (as measured by the Clinician-Administered PTSD Scale and the Timeline Follow 
Back) to identify differences in the predictive power of baseline dysregulation based on 
treatment type (i.e., RPT or COPE).  Thirdly, the study assessed longitudinal changes in emotion 
dysregulation over time (at baseline and at 1 week post-treatment), examining a relationship 
between change in emotion dysregulation (as measured by the DERS) and treatment type (i.e., 
RPT or COPE).  Lastly, we examined longitudinally changes in emotion dysregulation (as 









Individuals referred from the Addiction Institute of New York, and the Women’s Health 
Project Treatment Research Center, as well as participants referred from other sources, including 
those responding to advertisements in the local papers and on Craigslist were screened.  A total 
of 80 men and women were randomized into treatment conditions.  
Eligible participants were between 18 and 65 years of age and able to comprehend 
English.  All participants met DSM-IV-TR criteria for current drug or alcohol dependence and 
used illicit substances within the past 3 months.  Participants also met DSM-IV-TR criteria for 
current PTSD in response to an interpersonal trauma.  Participants all provided informed consent 
and understood all assessment instruments.  Participants all provided the name of at least one 
person who would know where to contact them if they were to move or change phone numbers.  
Participants were willing to commit to 12 therapy sessions and five research assessment 
interviews. 
Participants were deemed ineligible if they had a history of or current psychotic, 
schizoaffective, bipolar, eating, or dissociative identity disorder.  These individuals were not 
considered psychiatrically stable enough to tolerate or benefit from the proposed treatment.  
Participants, however, with other psychiatric disorders, including mood or anxiety disorders, 
were included, due to the high frequency of comorbid psychiatric disorders among patients with 
PTSD (Brady, Killeen, Saladen, Dansky, & Becker, 1994).  Additionally, participants who 
presented a serious homicide or suicide risk or were involved in a violent intimate partnership 
(perpetrator or victim) were ineligible for the study.  Participants already receiving PTSD-







initiated during the less than 8 weeks prior to study participation—were excluded from the study.  
Lastly, individuals with organic mental syndrome as indicated by a score of less than or equal to 
21 on the Mini-Mental Status Exam were not eligible for the study.  
Behavioral Interventions 
Cognitive-Behavioral Therapy in Conjunction with Prolonged Exposure (COPE).  
COPE is a manualized 12-week intervention, using cognitive-behavioral strategies and 
prolonged exposure techniques to decrease PTSD and SUD symptoms in individuals with 
concurrent PTSD and substance dependence.  COPE represents a combination of empirically 
validated and efficacious cognitive-behavioral treatments for substance dependence and PTSD 
(Carroll, Nich, & Rounsaville, 1998; Foa & Rothbaum, 1998).  In COPE, patients receive 
psychoeducation pertaining to the underlying principles of cognitive and exposure-based 
therapies in addition to the interrelatedness of PTSD and substance dependence.  Coping skills 
training, relapse prevention techniques, and cognitive restructuring are taught to reduce 
substance use severity.  In-vivo and imaginal exposure therapy techniques are used to reduce 
PTSD symptom severity.  The primary goals of COPE are to (1) educate patients about the 
relationship between substance dependence and PTSD, (2) initiate and maintain abstinence, and 
(3) reduce PTSD symptom severity. 
Relapse prevention treatment (RPT).  RPT is a widely used cognitive-behavioral skills 
training designed to initiate and maintain abstinence from various types of substance (Carroll, 
Rounsaville, & Gawin, 1991; Rawson, Obert, McCann, & Marinelli-Casey, 1993).  The RPT 
model is based on the concept that the same cognitive, behavioral, and affective mechanisms 







1985).  By using RPT as a comparison intervention, it was possible to examine the specific 
effects of exposure therapy integrated into a CBT platform. 
In general, RPT consists of the following elements: (1) psychoeducation about the 
biological, psychological, and social effects of addiction to and recovery from various 
substances; (2) identification of high-risk situations for and early signs of relapse; (3) 
development of coping skills for achieving abstinence—especially refusal and avoidance skills, 
behavioral skills for substituting drug use with drug-free behaviors in high risk situations, 
cognitive skills for overcoming cravings, drug-free stress management skills, and affective skills 
for labeling and expressing emotions without drugs; (4) increasing perceived self-efficacy to 
achieve and maintain abstinence; (5) development of cognitive and behavioral skills for 
preventing the abstinence violation effect; and (6) development of drug-free lifestyle behaviors. 
Measurement 
Demographic Measures 
Demographic and Treatment History Form (DEMO).  The DEMO is a structured 62-
item social and treatment history interview designed to provide basic demographic and life 
history information related to the course of illness, including: demographic variables, family 
history, age of onset of substance and/or psychiatric problems, history of hospitalizations, 
previous treatment, symptoms, and diagnoses (Hien & Zimberg, 1991).  The measure was 
administered five times: at baseline; immediately post-12-week intervention; and 1, 2, and 3 
months post-treatment.  
Any baseline variables including age, age of onset of psychiatric and SUDs, symptom 







age at which first trauma occurred)—which significantly differed across study arms—were 
treated as covariates and controlled for in the analyses. 
Trauma Symptoms Measure 
Clinician-Administered PTSD Scale (CAPS).  The CAPS is a structured, clinical 
interview for assessing the cardinal and hypothesized frequency and intensity of signs and 
symptoms of PTSD.  The CAPS measures DSM-IV-TR symptoms of PTSD, associated 
symptoms of PTSD, validity of responses, impairments in social and occupational functioning, 
and overall symptom severity.  It also measures the degree of improvements since an earlier 
rating.  The CAPS has demonstrated strong convergent validity with the Structured Clinical 
Interview for DSM-IV (SCID)–PTSD module  
(r = .83) and the PTSD Symptom Scale Interview (r = .73; Foa & Tolin, 2000).  The CAPS has 
also been found to have sound psychometric properties; test–retest reliabilities ranged from .77 
to .96 for the three symptom clusters and from .90 to .98 for the 17-item core symptom scale 
(Blake et al., 1995).  The measure was administered five times: at baseline; immediately post-12-
week intervention; and 1, 2, and 3 months post-treatment.  
Substance Use Measure 
Time Line Follow Back (TLFB).  The TLFB is a clinician-assisted measure to assess 
recent drinking behavior over the 90-day period prior to the interview.  Subjects retrospectively 
estimate their daily alcohol consumption while referencing a detailed calendar.  The participant 
is oriented to specific episodes of regular, erratic, or binge drinking by the clinician.  The TLFB 
is reliable and, in several studies, data obtained with a method like the TLFB have been sensitive 
to changes in alcohol consumption.  The TLFB has high temporal stability with most test–retest 







drug use patterns 90 days prior to treatment; it was then administered at each follow-up point 
(Sobell & Sobell, 1992, 1995, 2000).  The measure was administered five times: at baseline; 
immediately post-12-week intervention; and 1, 2, and 3 months post-treatment.  
Emotion Regulation Measure 
Difficulties in Emotion Regulation Scale (DERS).  The DERS is a 41-item self-report 
measure developed to assess clinically significant difficulties in emotion regulation.  DERS 
items were chosen to reflect difficulties within the following dimensions of emotion regulation: 
(a) awareness and understanding of emotions; (b) acceptance and emotions; (c) the ability to 
engage in goal-directed behavior, and refrain from impulsive behavior when experiencing 
negative emotions; and (d) access to emotion regulation strategies perceived as effective.  
Responses range from 1 to 5, with higher scores indicating greater difficulties in emotion 
regulation.  The total DERS was found to have good test–retest reliability (r = .88) and high 
internal consistency (α = .93); the subscales also had high internal consistency (i.e., Cronbach’s α 
> .80 for each).  Preliminary findings suggest adequate construct and predictive validity (Gratz & 
Roemer, 2004; Sloan & Kring, 2007).  The measure was administered five times: at baseline; 
immediately post-12-week intervention; and 1, 2, and 3 months post-treatment.  
Physiological Arousal Measure 
Electrodermal skin fluctuation.  Electrodermal skin fluctuation is an instrument 
commonly used in psychophysiology experiments to infer emotional state and cortical arousal 
(Ressler et al., 2004; Storm et al., 2002).  This methodology measures electrical conductance in 
the skin through detecting variance in sweat gland activity.  Because sweat glands become more 
active in association with the arousal, a higher number and amplitude of conductance 







physiological methodology to measure regulation of emotion strengthens the validity of self-
report emotion regulation findings. 
The study utilized the ProComp2 electrodermal skin fluctuation device (produced by 
Thought Technology).  Two sensors were placed on the participant’s hand, one touching the 
palm and the second attached to the pointer finger.  Once sensors were attached, a very slight 
electrical current ran through the electrodermal skin fluctuation device, which recognized 
variances in salt and water from sweat glands.  When the skin’s surface produces more sweat, the 
electrical conductivity increases, reflecting a higher reading on the device and indicating higher 
levels of stress.  The electrodermal skin fluctuation measure was administered during each of the 
12 individual therapy sessions.  
Physiological arousal was measured weekly during sessions using skin conductance 
fluctuations per minute and two measures were explored.  An average measurement was 
calculated across each session and change in average measurement was calculated.  Secondly, 
each session was divided into 10-minute epochs.  An average measurement was calculated for 
each 10-minute epoch and the peak rate epoch was determined.  Change in peak rate epoch 
across sessions was calculated.  
Data Analysis 
All data were entered into SPSS Version 21.0.  Initial frequencies were examined for 
outliers and checked against raw data.  Exploratory analyses were performed on the data to 
create descriptive statistics on the sample.  Alpha coefficients were computed to examine each 
scale’s reliability.  The associations between emotion dysregulation and other independent 
variables, such as treatment condition and symptom severity at baseline, were examined through 







background variables were performed using correlations, chi squares, t tests, and ANOVAs to 
check for possible covariates.  Research questions were answered using 2 × 2 × 2 ANOVAs. See 








Figure 1.  Will treatment type modify the relationship between baseline dysregulation, and 







CHAPTER 4: RESULTS 
Baseline Characteristics 
Table 1 depicts demographic characteristics in addition to variables related to 
pretreatment substance use, PTSD symptoms, and emotion dysregulation.  To review, 
participants ranged in age from 20 to 64, with a mean age of 39.8 years (SD = 11.9).  The sample 
was 66.3% male (n = 53) and 33.8% female (n = 27).  Over 75% of the participants indicated 
they were a racial/ethnic minority, with 56.3% identified as African American (n = 45) and 
21.3% identified as Hispanic (n = 17).  Over 90% of the sample was born in the United States (n 
= 73) and 93.5% of participants (n = 72) indicated that English was their first language.  In terms 
of education, participants attended, on average, 13.07 years of schooling (SD = 3.0).  At baseline 
assessment, 67.5% were employed in some fashion.  Regarding service utilization prior to study 
enrollment, 23.6% of participants (n = 17) reported receiving previous outpatient treatment for 
psychological problems; 55.6% (n = 40) reported receiving previous inpatient treatment for 
psychological problems; and 23.9% of participants (n = 17) reported previous trauma specific 
treatment.  At baseline assessment, 54.1% of the sample (n = 40) indicated they had at some 
point been prescribed psychotropic medication and nearly 20% of the sample (n = 13) reported at 
least one suicide attempt.       
Approximately 60% of participants met DSM-IV-TR criteria for PTSD (n = 50) while the 
remaining 37.5% demonstrated symptoms consistent with subthreshold PTSD (n = 30).  The 
total sample had a mean DERS score of 90.9 (SD = 22.4).  The subjects with DERS scores above 
the mean were considered to be high dysregulators (48.8%; n = 39); participants with DERS 








Baseline Participant Characteristics  
 
Total 
(N = 80) 
COPE 
(n = 40) 
RPT 
(n = 40) 












  40.8 
 
12.0 
Gender (% female)  33.8  35.0    32.5  
Race/ethnicity (%)       
African American/Black 56.3  52.5    60.0  
Caucasian 18.0  20.0    17.5  
Latino 21.3  22.5    20.0  
Other   3.8    5.0      2.5  
Marital status (%)       
Married  17.7  15.0    20.5  
Single 25.3  65.0    48.7  
Divorced/separated  57.0  20.0    30.8  
Years of education  13.1 3.0 13.2 3.1 12.9 3.0 
Employment (%)        
Employed 67.5  71.8    63.2  
Unemployed 14.3  10.3    18.4  
Student/retired/disabled 18.2  17.9    18.4  
PTSD diagnosis (% full)  62.5  65.0    60.0  
CAPS total, Baselinea 53.7 17.4 52.9 16.3   54.5 18.6 
Substance use days in last 7    4.4 2.5   4.5 2.5     4.3 2.4 
DERS total score, Baseline  90.9 22.4 89.5 23.0   92.2 21.9 
Therapy sessions attended    6.7 4.6   5.8 4.6     7.5 4.5 
Prior mental health treatment        
Inpatient (% Yes)  55.6   56.8    54.3  
Outpatient (% Yes)  23.6  22.9    24.3  
Trauma specific treatment 
(% Yes)  
23.9  22.9    25.0  
Treatment group (% RPT) 
 
50.0    0.0  100.0  
Note. Values are either means (with standard deviations) or percentages.  COPE = Concurrent Treatment of PTSD 
and Substance Use Disorders Using Prolonged Exposure; RPT = relapse prevention therapy.  PTSD = posttraumatic 
stress disorder; CAPS = Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation Scale.  
There were no statistical differences between treatment groups on any pretreatment variable.  







Half of the sample was randomized to the COPE treatment (n = 40) and half was 
randomized to RPT (n = 40).  Overall, treatment attendance ranged from 0 to 12 sessions; 
participants attended a mean of 6.7 sessions (SD = 4.6).  There were no statistically significant 
differences between treatment groups for the various baseline characteristics.  
Descriptive Statistics 
Table 2 depicts descriptive statistics for variables to be analyzed during correlation and 
regression analysis.  CAPS, Substance use days in last 7, and DERS, variables were all within 
acceptable limits for skewness and kurtosis.  All measures had good to excellent reliability  
(α > .8). 
In Table 3, correlation analyses examined potential non-hypothesized relationships 
between the dependent and independent variables.  Pearson coefficients showed there was a 
significant positive association between the CAPS follow-up and days used follow-up, r(41) = 
.36, p  = .02; DERS baseline and DERS follow-up, r(38) = .67, p < .01; CAPS baseline and 
CAPS follow-up, r(41) = .57, p < .01; and CAPS baseline and DERS follow-up, r(38) = .40, p = 
.01.  These correlations, while not hypothesized, are in the expected direction. 
Research Question 1: Analysis 
Pearson correlation analyses were conducted to determine whether there were 
relationships among baseline emotion dysregulation, as measured by the DERS, and baseline 
PTSD and SUD, as measured by the CAPS score, and substance use days in the last 7 at baseline 







Table 2  
Descriptive Statistics: Substance Use, Emotion Dysregulation, and PTSD Symptoms at Baseline  
Variable M SD Min Max Skewness Kurtosis Cronbach’s α 
 















Substance use days in last 7 
Baseline (n = 80) 
4.40 2.45 0.00 7.00 −.39 −1.21  
DERS baseline (n = 80) 90.90 22.36 50.00 160.00 .40 −.07 .93 
CAPS follow-up (n = 41) 37.25 24.77 0.00 100.00 .53 −.37 .93 
Substance use days in last 7 
Follow-up (n = 41) 
1.83 2.41 0.00 7.00 1.05 −.23  
DERS follow-up (n = 38) 80.22 21.18 46.00 124.00 .25 −1.05 .93 







Table 3  
Correlation Analysis of Independent and Dependent Variables 
 1 2 3 4 5 6 
       
1. Days used baseline —      
2. Days used follow-up .14 —     
3. DERS baseline −.12 −.03 —     
4. DERS follow-up −.29 .08 .674** —   
5. CAPS baseline .14 .17 .41** .40* —   
6. CAPS follow-up .06 .36* .07 .31 .54** — 
Note. CAPS = Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation Scale.   







As shown in Table 4, there was no significant correlation between the DERS baseline 
total score and substance use days in the last 7 at baseline.  A statically significant positive 
association was found between the CAPS baseline total score and the DERS baseline total score, 
r(80) = .41, p < 0.01, with DERS baseline total score explaining 17.4% of the variability in 
CAPS baseline total score.  Baseline emotion dysregulation is associated with baseline PTSD 
symptoms but not with baseline substance use.   
Research Question 2: Analysis 
A 2 × 2 × 2 (DERS group by treatment type by time) repeated measures ANOVA was 
conducted to determine whether treatment type moderates the relationship between baseline 
dysregulation, as measured by the DERS, and treatment outcomes, as measured by the CAPS 




Correlation Analysis Among Baseline DERS, Substance Use Days in the Last 7 Days, and CAPS 
















2.  CAPS, Baseline 
 
.41** —  
3.  Substance use days in 
the last 7, Baseline 
 
−0.12 .14 — 
Note. CAPS = Clinician-Administered PTSD Scale. DERS = Difficulties in Emotion Regulation Scale.   







Table 5 presents the results of the multivariate tests and shows a significant time effect, 
F(1, 37) = 25.78, p < .01, partial η2 = .59, and a trend for the hypothesized 2 × 2 × 2 interaction, 
F(1, 37) = 2.7, p = .08, partial η2 = .13.  Since the sample size is fairly small and the effect size 
of the interaction effect was medium (explaining 13% of the variability in outcome measures), 
univariate tests were conducted.  Tables 6 and 7 present results from the univariate tests. 
As shown in Table 6, time was found to be significant for days used, F(1, 37) = 28.67, p 
< .01, partial η2 = .44.  Additionally, there was a DERS group by treatment group interaction on 
PTSD outcomes, regardless of time, F(1, 37) = 5.06, p =.03, partial η2 = .12.  As a result, t tests 
were used to determine specifically which groups differed significantly. 
As shown in Table 8, among high dysregulators, the RPT group had higher mean CAPS 
total score (M = 57.04, SE = 5.37) as compared to the COPE group (M = 42.83, SE = 6.41) 
whereas among low dysregulators, RPT group did not have a significantly different mean CAPS 
total score as compared to the COPE group (Mdifference = 5.32, SE = 8.36, p =.53), regardless of 
time.  This difference indicates an unintentional lack of randomization on the PTSD severity 
scores.  See Figure 2 for a graphical depiction of the group differences.  
As shown in Table 7, time was found to be significant for days used, F(1, 37) = 33.84,  
p < .01, partial η2 = .48.  Additionally, the Time × Treatment Group × DERS Group interaction 
was found to be significant for days used, F(1, 37) = 5.281, p < .027, partial η2 = .125.  As a 








Multivariate Tests: Change in Outcomes Over Time by Baseline DERS Group by Treatment Group  














Intercept .90 160.78 2 36    .01** .90 
DERS group .11 2.26 2 36 .12 .11 
Treatment group  .06 1.18 2 36 .32 .06 













   .01** 
 
.59 
Time × DERS group .08 1.52 2 36 .23 .08 
Time × Treatment group  .04 .66 2 36 .52 .04 
Time × DERS group × Treatment group 
  
.13 2.70 2 36 .08 .13 
Note.  CAPS = Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation. 

























Note. CAPS = Clinician-Administered PTSD Scale. DERS = Difficulties in Emotion Regulation. 















Within subject effects       
Time 6344.48 1 6344.48 28.67   .01** .44 
Time × DERS group   591.60 1 591.60 2.67   .11 .07 
Time × Treatment group        0.02 1 0.02 .00   .99 .00 
Time × DERS group × Treatment group    187.97 1 187.97 .85   .36 .02 
Error   221.30 37 8188.04    
Between subjects effects       
DERS group    936.19 1 936.19 1.63   .21 .04 
Treatment group      72.01 1 72.01 0.13   .73 .003 
DERS group × Treatment group  2911.62 1 2911.62 5.06   .03* .12 
Error 
 








Univariate Analysis for Substance Use Symptoms by Time by Treatment Group by DERS Group 
(N=38) 
Effect MS df SS F p partial η2 
Within subject effects       
Time 161.60 1 161.60 33.84 
    0.01** 
0.48 
Time × DERS group 0.62 1 0.62 0.13   .72 0.003 
Time × Treatment group  6.31 1 6.31 1.32   .26 0.03 
Time × DERS group × Treatment group  25.22 1 25.22 5.28     .03* 0.13 
Error 221.30 37 8188.04    
Between subjects effects       
DERS group  11.07 1 11.07 1.66   .21 0.04 
Treatment group  12.14 1 12.14 1.82   .19 0.05 
DERS group × Treatment group  3.43 1 3.43 0.51   .48 0.01 
Error 
 
6.69 37 247.34    
Note.  CAPS = Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation. 







t Tests for Baseline DERS Group by Treatment Group on CAPS Score, Regardless of Time 
DERS Group 
Treatment 
Group Mean (SD) 
Mean 














 COPE (n = 10) 48.15 (5.37) 
High 
dysregulation 






 COPE (n = 7) 42.83 (6.41) 
 
Note.  CAPS = Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation. 









Figure 2.  Baseline DERS group by treatment group on CAPS score (N = 41).  CAPS = 
Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation; COPE = 
Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure; RPT = 
relapse prevention therapy. 
 
 
As shown in Table 9, the high baseline DERS group that received RPT treatment showed 
no change in days used.  All other groups, that is the high baseline DERS group that received 
COPE treatment, the low baseline DERS group that received COPE treatment, and the low 
baseline DERS group that received RPT treatment, showed significant change in days used from 
baseline to follow-up (see Table 9 for means pre- and post-treatment).  See Figure 3 for a 
graphical depiction of the interaction.  
Research Question 3: Analysis 
A 2 × 2 × 2 (DERS group by treatment type by time) repeated measures ANOVA was 
conducted to determine whether treatment type moderates the relationship between baseline 
dysregulation, as measured by the DERS, and change in emotion dysregulation, as measured by 








t Tests for Time by Treatment Group by DERS Group on Substance Use 
DERS Group 
Treatment 















 COPE (n = 10) 5.50 (2.46) 3.00 (2.75) 2.277 9 .049* 
High 
dysregulation 
RPT (n = 10) 3.20 (2.94) 2.20 (2.44) 0.866 9 .409 
COPE (n = 7) 
 
5.29 (1.98) 0.86 (1.46) 5.894 6 .001** 
Note.  CAPS = Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation; COPE = 
Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure; RPT = relapse prevention 
therapy. 






Figure 3.  t Tests for time by treatment group by DERS group on substance use (n = 41).  COPE 
= Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure;  







Table 10 presents the results of the univariate tests and shows a significant effect of time, 
F(1, 34) = 7.11, p = .01, partial η2 = .17, and a significant Time × DERS effect, F(1, 34) = 6.25, 
p = .02, partial η2 = .16, and a trend for the hypothesized 2 × 2 × 2 interaction, F(1, 34) = 3.40,  
p = .07, partial η2 = .09).  Since the sample size is fairly small and the effect size of the three-way 
interaction effect is small to medium (explaining 9% of the variability in outcome measures), 
post-hoc t tests were conducted.  Univariate tests also revealed a DERS group effect on change 
in DERS, regardless of time, F(1, 34) = 45.96, p <.001, partial η2 = .58.  As a result, t tests were 
used to determine specifically which groups differed significantly.  Tables 11 through 13 present 
results from the post-hoc t tests.  
 
Table 10 
Univariate Tests for Change in DERS by Time by Treatment Group by DERS Group (N = 38) 
Effect MS df SS F p 
partial 
η2 
Within subject effects       
Time 908.05 1 908.05 7.11 .01** .17 
Time × Treatment group 24.62 1 24.62 0.19 .66 .01 
Time × DERS group  798.61 1 798.61 6.25 .02* .16 
Time × DERS group × Treatment group  434.06 1 434.06 3.40 .07 .09 
Error 127.72 34 4342.32    
Between subjects effects       
Treatment group  529.24 1 529.24 1.70 .202 .05 
DERS group  14355.25 1 14355.25 45.96 .001** .58 
DERS group × Treatment group  704.02 1 704.02 2.25 .142 .06 
Error 
 
106118.74 34 106118.74    
Note.  DERS = Difficulties in Emotion Regulation. 








t Tests for Time by DERS Group on Change in DERS  






















15 107.40 (13.66) 94.71 (20.22) 2.82 14 .01* 
Note.  DERS = Difficulties in Emotion Regulation; COPE = Concurrent Treatment of PTSD and Substance Use 
Disorders Using Prolonged Exposure; RPT = relapse prevention therapy. 




t Tests for Time by Treatment Group by DERS Group on Change in DERS 















 COPE (n = 10) 
 
70.07 (8.12) 73.39 (12.85) −0.78 9 .458 
High dysregulation RPT (n = 9) 109.66 (10.68) 101.89 (16.98)  1.66 8 .135 
 COPE (n = 6) 104.00 (17.8) 83.92 (21.25)  2.38 5 .063 
Note.  DERS = Difficulties in Emotion Regulation; COPE = Concurrent Treatment of PTSD and Substance Use 
Disorders Using Prolonged Exposure; RPT = relapse prevention therapy. 
*p ≤ 0.05; **p ≤ 0.01 
 
 
Table 13  
t Tests for Baseline DERS group on Change in DERS, Regardless of Time 
DERS Group (n) Mean (SD) 
Mean 
Difference SE p 
 










High DERS group (17) 
 
99.87 (3.30) 
Note.  DERS = Difficulties in Emotion Regulation Scale. 







As shown in Table 11, the high baseline DERS group showed a significant change in 
DERS at follow-up (Mpre = 107.40, SD = 13.66; Mpost = 94.71, SD = 20.22, p = .01) as compared 
to the change in DERS found in the low baseline DERS group at follow-up. 
As shown in Table 12, the high baseline DERS group that received COPE treatment 
showed a change in DERS at follow-up at a trend level (Mpre = 104.00, SD = 17.80; Mpost = 
83.93, SD = 21.25, p = .063).  All other groups, that is the high baseline DERS group that 
received RPT, the low baseline DERS group that received COPE treatment, and the low baseline 
DERS group that received RPT, showed no significant change DERS total from baseline to 
follow-up (see Table 12 for means pre- and post-treatment).  See Figure 4 for a graphical 
depiction of the interaction.  
 
 







Lastly, as shown in Table 13, the high DERS group had higher mean DERS total score 
(M = 99.87, SE = 3.30) as compared to the low DERS group (M = 71.31, SE = 2.63), regardless 
of time.  This difference is a result of the high–low DERS grouping created for the 2 × 2 × 2 
analysis.  
Case Illustration 
The high baseline DERS group that received COPE treatment showed a trend level 
change in DERS at follow-up (Mpre = 104.00, SD = 17.80; Mpost = 83.93, SD = 21.25, p = .063).  
All other groups, specifically the high baseline DERS group that received RPT treatment, the 
low baseline DERS group that received COPE treatment, and the low baseline DERS group that 
received RPT treatment, showed no significant change DERS total from baseline to follow-up.  
To further explore the change in DERS over time among highly dysregulated individuals 
undergoing COPE, one case was selected for a case illustration.  The participant’s physiological 
arousal during sessions was examined using a skin conductance measure and both skin 
conductance level, a measure of overall arousal level, and skin conductance rate, a measure of 
the number of fluctuations in arousal per minute, were calculated.  
Table 14 depicts demographic characteristics in addition to variables related to 
pretreatment and follow-up substance use, PTSD symptoms, emotion dysregulation, and 
physiological arousal.  To review, the participant was a 51-year-old African American/Black 
male with some college education.  He received 12 sessions of treatment and showed a 38-point 
reduction in emotion dysregulation, as measured by the DERS; a 28-point decrease in CAPS 








Case Illustration Participant Characteristics  
Variable 
COPE 





Gender (% male)  100 
Race/ethnicity (%)  




Years of education  14 
Therapy sessions attended  12 
Baseline DERS group (% high dysregulation) 100 
DERS total score, Baseline  98 
DERS total score, Follow-up 60 
CAPS total, Baseline 28 
CAPS total, Follow-up 0 
Substance use days in last 7, Baseline  7 
Substance use days in last 7, Follow-up 1 
SCR, Session 1 (peaks per minute) 1.61 
SCR, Session 12 (peaks per minute) 1.06 
% Change in SCR  −34 
SCL, Session 1 2.41 
SCL, Session 12 1.34 
% Change in SCL 
 
−44 
Note.  Values are either raw scores or percentages.  COPE = Concurrent Treatment of PTSD and Substance Use 
Disorders Using Prolonged Exposure.  PTSD = posttraumatic stress disorder; CAPS = Clinician-Administered 





Figure 5 depicts the physiological arousal over the course of treatment.  With regards to 
physiological arousal, as measured by SCR, the COPE participant showed a steady increase in 
physiological arousal, peaking in the fourth session before his arousal decreased over the course 












Figure 6 depicts the COPE participant’s skin conductance during the first and last (12th) 
COPE session.  The COPE participant had an average SCR of 1.61 peaks per minute and an 
average SCL of 2.41 micro Siemens during Session 1.  During the 12th session, the COPE 
participant had an average SCR of 1.06 peaks per minute and an average SCL of 1.34 micro 
Siemens.  As compared to Session 1, the COPE participant’s overall arousal was 44% lower with 
34% fewer fluctuations during Session 12, indicating a lower level of arousal during the final 















CHAPTER 5: DISCUSSION 
Emotion dysregulation has been observed to be a shared feature of both PTSD and SUD 
(Hien et al., 2005).  Treatments for these complex comorbid problems utilize a variety of 
approaches.  However, to date, few studies have examined the effect of the various available 
treatments on emotion dysregulation in this population.  The present study attempted to extend 
the research on emotion dysregulation among the comorbid PTSD and SUD population.  It 
examined features associated with emotion dysregulation, associating dysregulation with other 
psychiatric symptoms affecting this clinical population.  Specifically, the study focused on 
baseline emotion dysregulation as a predictor of treatment outcomes and used a longitudinal 
design to assess changes in emotion dysregulation over time to determine the mutability of this 
complex factor in response to treatment.  Given the seriousness and prevalence of PTSD and 
SUD (van Dam et al., 2010), and the many impediments they pose to treatment efficacy, a more 
refined understanding of emotion dysregulation could support improved conceptualization and 
implementation of psychotherapeutic interventions for this population.  
A detailed discussion of study findings is presented in the next five sections, beginning 
with an overview of the main findings, briefly summarizing the results related to each of the 
research questions.  Additionally, research and clinical implications will be reviewed.  Lastly, 
limitations and future directions for research will be presented.  
Summary of Main Findings 
Emotion dysregulation is inherent to many forms of psychopathology (Bradley et al., 
2011).  Previous studies using non-clinical and community samples found associations between 
PTSD symptom severity and overall emotion dysregulation (Weiss et al., 2013).  Similar 







al., 2009).  People with severe PTSD and SUD symptoms are assumed to have high 
dysregulation.  This study examined features associated with baseline emotion dysregulation 
among a comorbid PTSD and SUD population and indeed, found a positive association between 
the CAPS baseline total score and the DERS baseline total score.  However, no significant 
correlation between the DERS baseline total score and substance use days in the last 7 at baseline 
was found.  Baseline emotion dysregulation was associated with baseline PTSD symptoms, but 
not with baseline substance use among people with comorbid PTSD and SUD.  The present 
study reinforces the findings of Weiss et al. (2013); Bonn-Miller, Vujanovic, Boden, and Gross 
(2011); and Tull, Barrett, McMillan, and Roemer (2007).  Greater difficulty in regulating 
emotions is associated with PTSD symptom severity.  Future research studies involving similar 
populations should take these findings into consideration.  
Self-medicating with alcohol and drugs can provide temporary relief from the 
dysregulated feeling states that are characteristic of PTSD (Hien et al., 2009).  Because of their 
long-standing chronic use of substances to manage affect, individuals with PTSD and SUD may 
not be aware of experiencing problems with emotion regulation.  Unlike the CAPS which is a 
30-item clinically administered interview protocol that is able to capture the nuances of multiple 
PTSD symptoms, the substance use measure utilized in this study focused on substance use 
frequency alone.  It is noteworthy that frequency is only one symptom of a SUD and may likely 
not have been a sensitive enough measure to capture how emotion regulation and substance use 
are related.  Additionally, though this study considered several aspects of emotion dysregulation 
including, impulse control, emotional awareness, access to regulation strategies, and emotional 
clarity, it is possible that the construct did not tap into addiction-related symptoms.  It is also 







measure asks for an overall rating of one’s ability to manage strong emotions.  Episodic use may 
be indicative of varying levels of emotion dysregulation.  In sum, it is possible that use needs to 
be at a certain level and/or with a certain frequency to be correlated with dysregulation.    
Exposure-focused treatments and skills-based treatments are premised on different 
emphases with respect to emotion dysregulation.  RPT aims to change behavior through a top-
down approach, examining cognitions in relation to affect.  COPE, the only exposure treatment 
developed to treat SUD, utilizes a bottom-up fear habituation processing model.  Specifically, the 
second research question in the present study explored whether treatment type moderated the 
relationship between baseline dysregulation, as measured by the DERS, and treatment outcomes, 
as measured by the CAPS and substance use days in the last 7 at follow-up.  Findings revealed a 
significant three-way interaction: Time × Treatment Group × DERS Group was significantly 
different across the substance use outcome measure.  Specifically, the high baseline DERS group 
that received COPE treatment, the low baseline DERS group that received COPE treatment, and 
the low baseline DERS group that received RPT treatment all showed significant change in 
number of days of use from baseline to follow-up; by contrast, the high baseline DERS group 
that received RPT treatment showed no change in number of days of use.  
These findings suggest that among highly dysregulated individuals with SUD and PTSD, 
a treatment focusing solely on the SUD will not garner positive changes in substance use 
frequency.  These results provide a strong indicator that treatments that do not directly discuss or 
integrate trauma cannot shift problematic substance use, especially among the highly 
dysregulated participants.  Not only is a treatment like COPE indicated, but indeed these findings 
provide some suggestion that RPT may be contraindicated or even iatrogenic for highly 







Najavits et al. (2005), and most recently, Mills et al. (2012), in challenging the commonly held 
view that patients with comorbid PTSD and SUD are inappropriate candidates for prolonged 
exposure (Becker, Zayfert, & Anderson, 2004).  Though it has been theorized that individuals 
with comorbid PTSD and SUD are too high risk to engage in exposure-based treatments, 
empirical research including the present study, have shown evidence to the contrary.  Patients 
with comorbid PTSD and SUD have shown the ability to tolerate and benefit from trauma-
focused treatment.    
Additionally, treatment group by DERS group, regardless of time, was found to be 
significant for PTSD symptoms indicating a difference in the level of PTSD symptoms between 
the two treatment groups.  More specifically, among high dysregulators, the RPT group had 
higher mean CAPS total score as compared to the COPE group, whereas among low 
dysregulators, RPT group did not have a significantly different mean CAPS total score as 
compared to the COPE group, regardless of time.  This difference indicates an unintentional lack 
of randomization at baseline.  Specifically, since participants were not matched on baseline 
emotion dysregulation during the randomization phase of the study, the RPT group had higher 
CAPS total score, regardless of time.  The groups were not equivalent on this variable.  
Randomization presumes equivalence across groups.  If equivalence is not established, 
group comparisons are problematic.  It is difficult, however, to always know which variables are 
important and should be considered in the randomization process.  Since the present study 
evidenced that emotion dysregulation is related to PTSD symptom severity, future studies 
focusing on individuals with PTSD should consider baseline dysregulation as a factor for 
randomization.  One challenge to considering baseline dysregulation in the randomization 







randomization phase.  The present study calculated a sample mean DERS score and grouped 
those above the mean into the high dysregulation group and those below the mean into the low 
dysregulation group.  Randomizing on dysregulation would require the a priori classification of 
dysregulation severity, which is not yet established in the literature. 
Emotion regulation describes the processes by which individuals influence expression of 
emotions, when emotions arise, and how they are experienced (Hien et al., 2009).  To the extent 
that certain emotion regulatory strategies are theorized to be more adaptive than others, it can be 
hypothesized that psychologically based treatments may affect emotion regulatory capacities.  
For example, individuals with comorbid PTSD and SUD often have a limited range of accessible 
emotional coping skills and are frequently over reliant on avoidant strategies in an attempt to 
manage intense feelings.  Exposure therapy, directly and experientially, addresses emotion 
regulation problems and associated physiological arousal through habituation to disrupted fear 
responses in the service of assimilating and integrating overwhelming experiences.  RPT for 
comorbid PTSD and SUD, on the other hand, focuses on identifying emotional states for the 
purpose of coping and managing intense emotion, so the treatment mainly works on developing 
skills and building coping strategies. 
Specifically, the third research question in the present study examined whether treatment 
type moderated the relationship between baseline dysregulation and dysregulation at follow-up.  
Findings revealed (at a trend level) that those in the high baseline DERS group who received 
COPE treatment had lower DERS at follow-up.  In contrast, all other groups, specifically the 
high baseline DERS group that received RPT, the low baseline DERS group that received COPE 
treatment, and the low baseline DERS group that received RPT, showed no significant change 







These results provide a speculation that among people with PTSD and SUD, those with 
high levels of emotion dysregulation may be particularly able to make use of the COPE 
treatment model.  Engagement in a treatment that directly addresses trauma memories may 
positively impact emotion regulation capacities among those with particular difficulty in that 
domain.  By reducing anxiety and increasing awareness, individuals no longer need to engage in 
emotional and behavioral avoidance.  By confronting the trauma directly, it is possible to find 
some degree of emotional mastery over overwhelming traumatic experiences.    
Additionally, the supplemental analysis of the skin conductance data provided descriptive 
information that depicted the physiological arousal of one participant in the high baseline DERS 
group who received COPE treatment.  The participant was a 51-year-old African 
American/Black male with some college education.  He received 12 sessions of treatment and 
showed a 38-point reduction in emotion dysregulation as measured by the DERS; a 28-point 
decrease in CAPS score; and a 6-day decrease in substance use days in the last 7 at follow-up.  
His physiological arousal pattern showed a decrease in arousal over time and was consistent with 
the change (at a trend level of p = .063) found in the high dysregulation COPE group’s change in 
DERS at follow-up.  
Clinical Implications 
Experts in the field of substance abuse treatment have historically been hesitant to use 
prolonged exposure to treat individuals with comorbid PTSD and SUD.  Exposure-based 
behavioral therapies are suspected to be contraindicated for people with addictions for fear of 
relapse, treatment dropout, increased acting-out behaviors, and dysregulation (van Minnen et al., 







with SUD as it was believed that these patients may be unable to cope with the intense emotions 
triggered during exposure to trauma memories (Foa & Rothbaum, 1998).   
According to the results of this dissertation study, highly dysregulated persons with 
PTSD and SUD undergoing COPE exhibited positive changes in emotion dysregulation, while 
the other groups did not.  Additionally, highly dysregulated individuals at baseline benefitted 
more from COPE than RPT with respect to change in substance use.  While RPT is an 
intellectual skill-based approach focusing on cognitions and behavior, COPE uses both cognitive 
strategies and emotion-focused exercises to more experientially and directly address affective 
experiences.  These results provide additional support for the use of integrated treatments for 
comorbid SUD and PTSD (Back, Waldrop, Hien, & Brady, 2006; Hien, Campbell et al., 2010) 
among highly dysregulated individuals.  
The sequential model of care for comorbid PTSD and SUD treats the substance use first 
and defers treatment of trauma-related issues.  The clinical rationale behind deferring trauma 
treatment relates to a fear of that unaddressed substance abuse could impede other therapeutic 
efforts and potentially cause relapse (Pitman et al., 1991; as cited in Back et al., 2006).  While 
RPT is often considered the gold standard addiction treatment (Carroll et al., 1994; as cited in 
Hien et al., 2004) the results from this exploratory study indicate that high baseline dysregulation 
renders RPT ineffective in a comorbid PTSD and SUD population.  This exploratory study 
highlights the importance of directly and explicitly addressing trauma to improve substance use 
outcomes for highly dysregulated individuals with this comorbidity.  
Patients sharing DSM-IV-TR diagnoses of PTSD and SUD are not a homogenous 
population.  This analysis demonstrated that a one-size-fits-all approach has limited value for 







based on their specific needs and characteristics.  Specifically, different degrees of emotion 
dysregulation should be accounted for in order to provide a patient with matched clinical care.  
This dissertation indicates that an assessment of pretreatment emotion dysregulation can assist 
treatment efficacy.  Additionally, this exploratory study furthers the work of Mills et al. (2012) 
by emphasizing that highly dysregulated populations with PTSD and SUD are able to both 
tolerate and benefit from exposure treatment.  
Traditional intervention research has focused on comparing how groups of individuals 
receiving an experimental treatment compared to a control group.  This approach provides 
information about treatments for selected groups of people, but says little about choosing the best 
treatment for a specific individual.  As the health care landscape shifts to providing more 
personalized care, it is important to consider individual characteristics, like emotion 
dysregulation, to optimize outcomes.  Researchers are developing ways to better predict patients’ 
responses to targeted treatments; however, determining which factors have the most clinical 
significance is paramount (Hamburg & Collins, 2010).  The success of personalized medicine 
depends on having accurate assessments that identify patients who can benefit from targeted 
therapies (Hamburg & Collins, 2010).  This study may help to guide treatment customization 
based on interactions between emotion dysregulation and intervention focus.  Trauma processing 
psychotherapies, like COPE, that provide opportunity for meaning-making and trauma 
integration, may be better aligned for individuals who struggle in those domains as they pertain 








 Findings from an ANOVA identified a relationship between pretreatment levels of 
dysregulation and CAPS scores by treatment type.  Among high dysregulators, the RPT group 
had higher mean CAPS total score as compared to the COPE group, whereas among low 
dysregulators, the RPT group did not have a significantly different mean CAPS total score as 
compared to the COPE group, regardless of time.  This difference is indicative of an 
unintentional lack of randomization at baseline.  This finding suggests that it is appropriate to 
stratify study samples by emotion dysregulation, as it is frequently associated with outcomes of 
interest in a comorbid PTSD and SUD population.  Future studies involving samples with PTSD 
should consider randomizing on this factor.     
Limitations and Future Directions 
This exploratory study suggests the importance of directly discussing trauma in treatment 
for highly dysregulated people with comorbid PTSD and SUD.  These results, however, must be 
interpreted with caution due to the small sample size.  The interaction effects demonstrated 
within this dissertation indicate the importance of continuing the essential line of inquiry into 
emotion dysregulation and treatment matching with studies using larger samples.     
Emotion dysregulation is known to be correlated with substance use severity (Suh et al., 
2008); however, this study demonstrated that baseline emotion dysregulation was not associated 
with baseline substance use frequency among people with comorbid PTSD and SUD.  Future 
research on this topic should look deeper into the data to address a more complete picture of the 
relationship between baseline substance use and baseline emotion dysregulation.  Future studies 
should include measures of not only substance use frequency, but of quantity, cravings, and 







used to better capture the complexities of substance use severity, as it accounts for the impact of 
substance use on living.  Additionally, this study collapsed all categories of substances together 
(i.e., alcohol, cannabis, cocaine, etc.) when describing substance use.  Alternatively, separating 
out classes of drugs may provide a more accurate picture of use patterns.   
Emotion dysregulation has multiple facets.  This study used a total composite score from 
the DERS self-report measure.  Future research might benefit from looking at specific 
dimensions of emotion dysregulation.  For example, the DERS can be broken down into four 
indices: (1) awareness and understanding of emotions; (2) acceptance of emotions; (3) the ability 
to engage in goal-directed behavior, and refrain from impulsive behavior when experiencing 
negative emotions; and (4) access to emotion regulation strategies perceived as effective.  These 
indices may all function differently with respect to PTSD and SUD.  Additionally, future studies 
may benefit from using a less dichotomous measure of emotion dysregulation.  By 
acknowledging that emotion dysregulation exists on a spectrum, future studies might be 
advantaged by considering certain levels of emotional expressiveness or dysregulation to be 
advantageous, normative, or even healthy.   
This study relied heavily on the use of an emotion dysregulation self-report measure.  
The case illustration, however, utilized skin conductance data.  The use of physiological 
measures on a larger scale would address both the less subjective and less conscious aspects of 
arousal and potentially dysregulation.  While skin conductance is widely used to index 
sympathetic arousal, it generally does not differentiate between positive and negative emotion 
(Dawson, Schell, & Filion, 2007).  Additionally, approximately 10 to 25% of participants are 
estimated to be hypo-responsive with respect to their electrodermal response; it may not be 







(Braithwaite, Watson, Jones, & Rowe, 2013).  Lastly, external factors such as temperature and 
internal factors such as medication can affect galvanic skin response measurements, which can 
lead to inconsistent results.  Future studies may include heart rate variability as an additional or 
alternative physiological measure of arousal.  Research has shown that heart rate variability 
reflects sympathetic as well as parasympathetic activation, and it is sensitive to changes in 
arousal (Thayer, Ahs, Fredrickson, Stollers, & Wager, 2012). 
Lastly, functional neuroimaging studies have implicated multiple regions of the brain, 
including the right ventrolateral prefrontal cortex, amygdala, and dorsal anterior cingulate cortex, 
in the regulation of positive and negative emotions (Etkin, Egner, & Kalisch, 2011; Ochsner & 
Gross, 2005; Kalisch, 2009; Kanske, Heissler, Schönfelder, & Wessa, 2011).  It has been 
observed that dysfunction in these regions can lead to disturbances in emotional regulation (i.e., 
hypo- or hyper-arousal) and contribute significantly to impaired functioning underlying a variety 
of psychological disorders, including PTSD and SUD (Teicher, 2000; Cooper et al., 1995; 
Thorberg, & Lyvers, 2006).  Further, fMRI studies directly examining the neural correlates of 
emotion regulation among clinical populations could help to clarify the basic mechanisms by 
which emotions are regulated and demonstrate the efficacy of specific treatments to ameliorate 
deficits in this domain.   
Conclusion 
As a contribution to research and clinical practice, the current exploratory project 
provided new evidence that exposure therapy can be tolerated by and beneficial to highly 
dysregulated persons with PTSD and SUD.  Contrary to expectations in the field, participants 
randomized to receive the exposure-based intervention did not demonstrate poorer substance use 







provide strong support for the COPE treatment as more efficacious than RPT in reducing 
emotion dysregulation and substance use frequency among individuals with high levels of 
baseline dysregulation.  Furthermore, this dissertation suggests that psychotherapy focusing only 
on substance use (e.g., RPT) may be contraindicated for highly dysregulated individuals with 
comorbid PTSD and SUD, as their substance use frequency did not decrease over time.  This 
study supports the idea that the complex presentations of individuals with PTSD and SUD should 
not be a deterrent to providing trauma-focused treatment.  
Knowing that specific alignments of emotion dysregulation and treatment types have 
differential effects on therapeutic outcomes helps to better match individuals with treatments and 
provide ways for therapy to be more effective.  This exploratory study adds to what is known 
about patient characteristics as pretreatment predictors of outcome and enhances the potential of 
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